National Pharmaceutical Pricing Authority (nppa)

The 33 drugs includes two each from JB Chemicals and Pharmaceuticals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharmaceutical, and Sanofi India and one from Torrent Pharma.

Economic Survey 2023: Govt keeping check on drug prices through direct price control, Janaushadhi stores

Strap: In the report, measures by the government that are adopted to make medicines affordable for the citizens, have been mentioned

Doctors’ body pitches for capping trade margin at 30% for all drugs in India

The demand, aimed at bringing relief to patients, comes at a time when the government is already considering limiting profit margins for a large number of commonly used medicines

Pharma pricing regulator fixes cost of 84 formulations; medicines for Type-2 diabetes, blood pressure

The drug formulations whose prices have been fixed include those used in the treatment of type 2 diabetes, high blood pressure, and gastrointestinal disorders.

Explainer I How the drug price regulator’s order raising the cap on prices of essential medicines by 10.7% may hit you 

Activists point that as the current drug pricing regime does not cover essential drugs in all their strengths and presentation, patients lose out on many counts

Kamlesh Kumar Pant appointed new NPPA chairman

The pharmaceutical pricing agency was currently headed by IAS officer Shubhra Singh, who was appointed to the post in 2018.

3-Point Analysis | NPPA hikes ceiling price for 21 drugs

The move is expected to make medicines available as companies faced a rise in prices of active pharmaceutical ingredients (APIs), a major raw material.

Drug pricing regime: Pharma companies express relief, health activists miffed

Indian pharmaceutical industry was rattled by the decision of former NPPA chairman Bhupendra Singh, who used special powers conferred under Paragraph 19 of the Drug Price Control Order (DPCO) 2013, to slash prices of hundreds of drug formulations, which were not part of National List of Essential Medicines (NLEM).

Manipal-TPG eyes majority stake in Medanta, values co at Rs 6,000 crore: Report

Manipal-TPG is likely to offer a valuation of Rs 6,000 crore for Medanta

NPPA to be revamped, will regulate prices more than fixing them

The NPPA is responsible for regulating drug prices and ensuring availability of medicines

RK Vats gets additional charge of NPPA chairmanship

Vats holds multiple positions including that of Director General (DG) of Central Government Health Scheme (CGHS). He is also the Chairman and Managing Director of HLL Lifecare Limited.

Over 3.4 lakh imported DES distributed in India in 2017: NPPA

The second most sold was DES priced up to Rs 15,000 at 1,10,289 units, garnering 32 per cent of the sales.

Syringes, needles to become cheaper as manufacturers cap trade margins at 75%

Prices of syringes and needles are likely to come down sharply as the manufacturers have decided to cap trade margins at 75% after the country’s drug price watchdog asked companies to regulate prices.

NPPA fixes ceiling price of 39 more drug formulations

The National Pharmaceutical Pricing Authority (NPPA) said while the ceiling price of 18 scheduled formulations has been fixed, that of 21 has been revised.

NPPA fixes prices of 31 more drug formulations

With the latest additions, the government has brought 761 drug formulations under price control in the National List of Essential Medicines (NLEM) since April 2016.

Here's what happened in the pharma sector last week

Fourth quarter earnings, some big generic approvals in US, NPPA's notices to drug makers for non-compliance with pricing rules and GST rate announcement were the highlights of the week.

NPPA issues notices to Lupin, Ranbaxy, others for selling FDCs without price approval

“These companies have launched formulations by altering a scheduled formulation with strength/dosage other than as specified in DPCO, 2013 and secondly in combination with other non-scheduled medicines without even applying for price approval from NPPA as required under Para 1 (2) of DPCO, 2013,” NPPA said.

RSS outfit writes to PM Modi, accuses Niti Aayog, bureaucrats of meddling with drug pricing

The letter accused bureaucrats of three ministries — Health and Family Welfare, Commerce and Industry and Chemicals and Fertilisers and Niti Aayog — colluding with pharmaceutical industry.

Under cost pressure, Abbott to urge NPPA to allow withdrawal of stents again

Last week, Indian drug regulator NPPA rejected applications filed by Abbott and Medtronics to withdraw their stent products from market technical grounds.

Capped stent prices include 8% trade margin, says regulator

Data put out earlier by NPPA pointed out that distributors had trade margins between 13 and 196 percent for sale of stents to hospitals, while hospitals enjoyed a margin between 11 percent and 650 percent on sales to patients.

NPPA simplifies rules to ensure no stents shortage to patients

NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients.

Heart of the matter: 5 things to know about pricing of stents

The data put out by NPPA on its website indicates a massive escalation of stent costs often by as much as 10 times by the time the implant reaches patient from manufacturer.